Inovio announces positive HPV vaccine PhIIb results; NanoBio's genital herpes candidate shows efficacy in animal model;

Tools

> Inovio Pharmaceuticals ($INO) reported positive Phase IIb studies of its VGX-3100, announcing that in women with high grade cervical neoplasia, the immunotherapy produced killer T cells that were able to clear lesions and the HPV virus itself. Release

> Ann Arbor, MI-based NanoBio announced that its adjuvanted genital herpes vaccine candidate showed efficacy in guinea pigs. Statement

> IDK Biologika opened its first U.S. vaccine manufacturing plant in Rockville, MD. Announcement

> Abivax named Dr. Jean-Marc Steens its chief medical officer. Release

Comments